Checkpoint Capital L.P. 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Checkpoint Capital L.P. disclosed 16 US equity positions worth $201.6m in its Q3 2024 13F filing. The largest position was ARGX at 24.9% of the reported book, followed by RYTM and PHAT.
What did Checkpoint Capital L.P. own in Q3 2024? Top 16 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | ARGX ARGENX SE | Healthcare | 24.9% | $50.1m | 92,500 | – | |
| 2 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 17.2% | $34.8m | 663,381 | – | |
| 3 | PHAT PHATHOM PHARMACEUTICALS INC | 13.5% | $27.2m | 1,504,307 | – | ||
| 4 | CYTK CYTOKINETICS INC | Healthcare | 12.2% | $24.6m | 466,813 | – | |
| 5 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 9.3% | $18.8m | 209,632 | – | |
| 6 | AVADEL PHARMACEUTICALS PLC | 7.2% | $14.4m | 1,100,000 | – | ||
| 7 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 5.4% | $10.8m | 240,000 | – | |
| 8 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.1% | $4.3m | 380,000 | – | |
| 9 | TCRX TSCAN THERAPEUTICS INC | 2.0% | $4.1m | 825,341 | – | ||
| 10 | ATYR ATYR PHARMA INC | Healthcare | 1.5% | $3.1m | 1,736,477 | – | |
| 11 | SLNOEUR SOLENO THERAPEUTICS INC | 1.5% | $2.9m | 57,983 | – | ||
| 12 | CDTX CIDARA THERAPEUTICS INC | 1.0% | $2.0m | 182,426 | – | ||
| 13 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.0% | $1.9m | 157,514 | – | |
| 14 | IRON DISC MEDICINE INC | Healthcare | 0.6% | $1.3m | 25,543 | – | |
| 15 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.4% | $835.0k | 250,000 | – | |
| 16 | ALLKGUSD ALLAKOS INC | 0.2% | $424.6k | 649,957 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.